Curbing Tumor Growth (IMAGE)

Boston Children's Hospital

Curbing Tumor Growth

Caption

Tested in mice, the engineered dual complementary liposomes loaded with doxorubicin (DCL-Dox) inhibited the growth of triple-negative breast tumors, by about 70 percent as compared with sham treatment and 40 percent as compared with free doxorubicin (not packaged in liposomes). They also outperformed liposomes targeting either ICAM1 alone or EGFR alone.

Credit

Guo <em>et al</em>., <em>Sci. Adv</em>. 2019; 5 : eaav5010

Usage Restrictions

Please credit as indicated.

License

Licensed content

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.